LOS ANGELES, May 12, 2005 (PRIMEZONE) -- SmallcapInsights.com, http://www.SmallcapInsights.com, the online source for exclusive commentary, research, interviews and other key investor information, has announced the availability of an online interview with Dr. James Winkelman, Chair of the Scientific Advisory Board of Xenomics (OTCBB:XNOM), a developer of next-generation medical DNA technologies.
In the audio interview, Dr. Winkelman provides an overview of the wide variety of diseases and conditions that Transrenal-DNA (Tr-DNA) testing methods can detect or monitor. Xenomics is extending its discovery of transrenal DNA - that is, DNA from inside the body compartment that has passed through the kidneys into the urine -- to create a proprietary technology platform to address a range of serious medical conditions, including AIDS and tuberculosis, as well as prenatal genetic testing for fetal chromosomal abnormalities such as Down syndrome.
"Customarily, it was thought that the DNA that actually appeared in urine was only that which arose from cells that were shed into the urine, such as those from the urinary tract," said Dr. Winkleman. "The findings at the basis for all of this work with transrenal-DNA, is that the accepted wisdom was wrong. Because in fact, DNA from cells elsewhere in the body get through the kidney and into the urine." Dr. Winkelman also discusses the various potential advantages presented by use of Tr-DNA medical tests, which includes such factors as accuracy, breadth of diagnostic information, relatively low costs, non-invasiveness and ease of utilization.
The streaming audio interview can be accessed at http://www.SmallcapInsights.com. Registration to listen to the interview is free.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal-DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal genetic testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://www.trilogy-capital.com/tcp/xenomics/website.html. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.
About SmallcapInsights.com
SmallcapInsights.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. SmallcapInsights.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on SmallcapInsights.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.SmallcapInsights.com.
Forward-Looking Statements
Statements made on SmallcapInsights.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by SmallcapInsights.com.
Compensation and Other Disclosures
SmallcapInsights.com is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by SmallcapInsights.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from Xenomics of $10,000 per month through January 2006 and thereafter for so long as Trilogy is retained to provide investor relations services. The Company issued Trilogy warrants to purchase 1,000,000 shares of Common Stock of the Company at an exercise price of $2.95 per share (the "Warrants"). The Warrants issued to Trilogy are exercisable upon issuance and expire on January 10, 2008. In the event the Company proposes to register any of its Common Stock under the Securities Act of 1933 for sale in connection with a public offering of Common Stock, the Company will give written notice to Trilogy and will include in such registration statement any of the shares of Common Stock underlying the Warrants which Trilogy may request be included. The offer and sale of these securities was made in reliance on Section 4(2) of the Securities Act of 1933, as amended. The offer and sale of the Warrants did not involve a public offering.